A journey from basic stem cell discovery to clinical application: The case of adventitial progenitor cells

Helen L. Spencer, Sadie C. Slater, Jonathan Rowlinson, Tom Morgan, Lucy A. Culliford, Martin Guttridge, Costanza Emanueli, Gianni Angelini, Paolo Madeddu

Research output: Contribution to journalArticlepeer-review

Abstract

Ischemia is a leading cause of death in the western world. Regenerative medicine aims to improve healing of ischemic injury by complementing pharmacologic/interventional treatments. Navigating regenerative therapies from 'bench-to-bedside' is a multistep time-consuming process, balancing cell expansion, purity, safety and efficacy while complying with regulatory guidelines. Studies started in academic laboratories unused to long-term planning often fail because of poor strategy design, lack of contingency plans or funding. We provide a strategic insight into our translation of saphenous vein-derived adventitial progenitor cells into a clinical grade product to treat angina. We discuss discovery phases, introduction of standard operating procedures and upgrade to clinical standards. We also examine contractual aspects of transferring to GMP-accredited facilities for clinical production and unexpected hurdles.

Original languageEnglish
Pages (from-to)39-47
Number of pages9
JournalRegenerative Medicine
Volume10
Issue number1
DOIs
Publication statusPublished - Jan 1 2015

Keywords

  • cell therapy
  • GMP
  • ischemia
  • pericytes
  • regenerative medicine
  • stem cell

ASJC Scopus subject areas

  • Biomedical Engineering
  • Embryology

Fingerprint

Dive into the research topics of 'A journey from basic stem cell discovery to clinical application: The case of adventitial progenitor cells'. Together they form a unique fingerprint.

Cite this